News

Fortified salt operations resume in Haiti

Author: James Reimer

Father Michelet Dorescar

According to Fr. Michelet Dorescar, General Manager of the CSC Salt Project, the facility in downtown Port-au-Prince, which produces its fortified salt marketed under the trade name Bon Sel Dayiti, resumed normal operations on Tuesday, July 10, after being closed on the preceding Saturday and Monday.

 

Most importantly, all employees and their families are safe and were kept out of harms way during the weekend protests.

Read More

Community research collaboration creates better system for treating trauma patients

Author: Brandi Klingerman

Frank Castellino

Trauma, or any kind of severe physical injury, continues to be today’s leading cause of death for people 46 and younger in the United States. In 2007, Dr. Scott Thomas and Dr. Mark Walsh of Memorial Hospital in South Bend were looking for a better way to treat trauma patients who arrived in the emergency room (ER) with excessive bleeding. Their search eventually led to a translational research collaboration with the W. M. Keck Center for Transgene Research at the University of Notre Dame and the development of a new method for treating trauma patients.

Read More

Inaugural Woodward Family Endowment for Excellence in NDnano Undergraduate Research Awarded

Author: Brandi Klingerman

Margo Waters Excerpt Photo

Rising junior Margo Waters, a science-business major, has received the first Woodward Family Endowment for Excellence in NDnano Undergraduate Research. The endowment is named after the Woodward Family and it will fund Waters’ 2018 NDnano Undergraduate Research Fellowship (NURF) in the lab of Prakash D. Nallathamby, research assistant professor of aerospace and mechanical engineering and affiliated member of NDnano

Read More

Notre Dame licensee Hsiri Therapeutics enters into agreement for the treatment of mycobacterial diseases

Author: Nick Swisher

Dome And Reflection 250

University of Notre Dame licensee Hsiri Therapeutics, Inc., with its corporate headquarters located in Media, PA, has entered into a license agreement with Shionogi & Co., Ltd. regarding a collaborative licensing, research and development program to discover and develop novel therapeutics for non-tuberculous mycobacterial (NTM) diseases and tuberculosis (TB).

Read More